|
Indications and Dosage
Intramuscular
Prophylaxis of Haemophilus influenzae type B disease in children Child: Primary immunisation: ActHIB, Hiberix 3 doses of 0.5 mL each, given at 2, 4, 6 months of age. Booster: ActHIB 15-18 months; Hiberix 12 months: 0.5 mL as a single dose. Primary immunisation: PedvaxHIB 2 doses of 0.5 mL each, given at 2, 4 months of age. Booster: 12-15 months 0.5 mL as a single dose.
|
|
Contraindications
Hypersensitivity. Acute severe febrile illness.
|
|
Special Precautions
Patient with moderate or severe acute illness (with or without fever), bleeding disorders (including thrombocytopaenia), severe immunosuppression. Children. Pregnancy and lactation. Postpone vaccination in case of febrile or acute disease. Not intended for the treatment of Haemophilus influenzae infections.
|
|
Adverse Reactions
Significant: Anaphylactoid/hypersensitivity reactions, syncope.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea. General disorders and administration site conditions: Inj site reactions (e.g. pain, redness, bruising, swelling); fever, irritability, fatigue. Infections and infestations: Conjunctivitis, otitis media. Metabolism and nutrition disorders: Loss of appetite. Psychiatric disorders: Somnolence, nervousness. Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection. Skin and subcutaneous tissue disorders: Rash. |
|
Parenteral: C
|
|
Monitoring Parameters
Monitor for hypersensitivity reactions, 15 minutes after administration.
|
|
Drug Interactions
Increased risk of bleeding with anticoagulants. Decreased therapeutic effect and immune response with immunosuppressive therapies (e.g. high dose corticosteroids).
|
|
Lab Interference
May interfere with interpretation of urine antigen detection tests.
|
|
Action
Description:
Mechanism of Action: Haemophilus b (Hib) conjugate vaccine (meningococcal protein conjugate) provides active immunity by inducing production of anticapsular antibodies that protect against infection caused by H. influenzae type b. Onset: Immunity: Approx 2 weeks. Duration: Immunity: Antibody concentration >1 mcg/mL: Several years. |
|
Storage
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
|
|
MIMS Class
|
|
ATC Classification
J07AG - Haemophilus influenzae B vaccines ; Used for active immunizations.
|
|
References
ActHIB (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/09/2018. Anon. Haemophilus b Conjugate Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 31/07/2018. Anon. Haemophilus b Vaccine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 31/07/2018. Buckingham R (ed). Haemophilus Influenzae Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/07/2018. PedvaxHIB (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 31/07/2018.
|
Sign Out
